World Lifestyler
  • Art & Culture
    • Architecture
    • Art & Exhibitions
    • Books
    • Design
    • Film & Music
  • Competitions
    • Dining Experiences
    • Hotel Stays
    • Luxury Experiences
    • Product Giveaways
    • Reader Exclusives
    • Travel Giveaways
  • Food & Drink
    • Chefs
    • Coffee Culture
    • Food Destinations
    • Recipes
    • Restaurants
    • Wine & Spirits
  • Lifestyle
    • Design
    • Fashion
    • Health & Wellbeing
    • Homes & Property
    • Love & Romance
  • People
    • Creatives
    • Entrepreneurs
    • Icons
    • Interviews
    • Profiles
    • Rising Talent
  • Travel
    • Adventure & Experience Travel
    • City Guides
    • Destinations
    • Hotels
    • Secret Spots
    • Travel Trends
  • Art & Culture
    • Architecture
    • Art & Exhibitions
    • Books
    • Design
    • Film & Music
  • Competitions
    • Dining Experiences
    • Hotel Stays
    • Luxury Experiences
    • Product Giveaways
    • Reader Exclusives
    • Travel Giveaways
  • Food & Drink
    • Chefs
    • Coffee Culture
    • Food Destinations
    • Recipes
    • Restaurants
    • Wine & Spirits
  • Lifestyle
    • Design
    • Fashion
    • Health & Wellbeing
    • Homes & Property
    • Love & Romance
  • People
    • Creatives
    • Entrepreneurs
    • Icons
    • Interviews
    • Profiles
    • Rising Talent
  • Travel
    • Adventure & Experience Travel
    • City Guides
    • Destinations
    • Hotels
    • Secret Spots
    • Travel Trends
No Result
View All Result
WORLD LIFESTYLER
No Result
View All Result
Home Press Releases Press Releases - Lifestyle

Mary’s Medicinals Announces Its Intention to Participate in the Newly Announced Medicare and Medicaid CMS Trial Program with Its Award-Winning Cannabinoid-Based Wellness Products

Cision PR Newswire by Cision PR Newswire
April 2, 2026
in Press Releases - Lifestyle
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

DENVER, April 1, 2026 /PRNewswire/ — Mary’s Medicinals, a subsidiary of MM Brands Inc. (MM Brands), officially announced today its intent to participate in the newly established Centers for Medicare & Medicaid Services (CMS) cannabinoid therapy trial program. Launched today under the CMS Innovation Center, the initiative follows the CMS announcement that cannabinoid-based medicines will be available under the Substance Access Beneficiary Engagement Incentive (BEI) program.


MM Brands logo Dixie & Mary's Medicinals

Under the new BEI framework, CMS has established eligibility for products containing up to 3 mg of tetrahydrocannabinols per serving. This threshold allows for the inclusion of non-intoxicating, full-spectrum hemp-derived CBD products, a category where Mary’s Medicinals has led since 2013.

The program aims to facilitate access to reliable cannabinoid therapies through established healthcare models under the Accountable Care Organizations (ACO) REACH program and the Enhancing Oncology Model (EOM). Beginning in 2027, eligible patients will have access through the Long-term Enhanced ACO Design (LEAD) model.

By providing access to efficacious, standardized products, the program seeks to evaluate the impact of cannabinoids on patient outcomes and their potential as alternatives to traditional pharmaceutical therapies.

“We look forward to working within the CCMI program to provide its participants with access to reliable products that can improve the lives of millions of patients,” said Joe Bayern, CEO of Mary’s Medicinals and MM Brands. “We are confident that the results of this program will create a formal pathway toward natural alternatives to opioids and synthetic prescription drugs.” Bayern added, “Mary’s has a long history of providing therapeutic benefits to our consumers. It is encouraging to see CMS acknowledge these benefits and join us in redefining the perception of cannabinoid-based therapies.”

About Mary’s Medicinals

Mary’s Medicinals is a pioneer in the cannabis industry, known for its “science-first” approach to product development. By combining rigorous lab standards with innovative delivery technology, Mary’s Medicinals provides a portfolio of products to offer a reliable alternative for those seeking the therapeutic benefits of cannabis with the accuracy of modern medicine.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/marys-medicinals-announces-its-intention-to-participate-in-the-newly-announced-medicare-and-medicaid-cms-trial-program-with-its-award-winning-cannabinoid-based-wellness-products-302732181.html

SOURCE MM Brands Inc.

Cision PR Newswire

Cision PR Newswire

Related Posts

The One Where SHEGLAM Meets FRIENDS

October 26, 2026

Rapidus and HCLTech announce partnership for next-generation semiconductor technologies

October 26, 2026

Parloa’s Agent Management Platform now sold as an SAP Solution Extension for agentic customer interactions

October 26, 2026

Temu Partners with Spain’s Recyclia to Support Seller Extended Producer Responsibility

October 26, 2026

SUNON Brings AI, Nature and Human-Centered Design to ORGATEC 2026

October 26, 2026

Innovent Announces NMPA Acceptance of a New Indication Application of Sintilimab for the Treatment of Advanced Melanoma

October 26, 2026

Popular News

  • How to Go 2x Long Anthropic (ANT): Leverage Shares by Themes Explains ANUU, the 2x Leveraged Anthropic ETF Launching Monday

    0 shares
    Share 0 Tweet 0
  • Mendez & Sanchez Finds Three Counties Accounted for Nearly Two-Thirds of California Rideshare Trips

    0 shares
    Share 0 Tweet 0
  • Highmark Health Reports Revenue of $26.5 billion, $741 million in Operating Income, for Nine Months ended Sept. 30, 2026

    0 shares
    Share 0 Tweet 0
  • AZ Blue Health Choice Expands Access to Resources for Page Families

    0 shares
    Share 0 Tweet 0
  • Payoneer Receives OCC Conditional Approval to Form Stablecoin National Trust Bank

    0 shares
    Share 0 Tweet 0

About & Contact

  • About Us
  • Branding Style Guide
  • Contact Us
  • Help Centre
  • Media Kit
  • Site Map

Explore Content

  • Events
  • Newsletter
  • Press Releases
  • Topics

Legal & Privacy

  • Advertiser & Partner Policy
  • Communications & Newsletter Policy
  • Contributor Agreement
  • Copyright Policy
  • Privacy Policy
  • Prohibited Content Policy
  • Terms of Service

Tiny Media Brands

  • Silicon Valleys Journal
  • The AI Journal
  • The City Banker
  • The Wall Street Banker
  • World Lifestyler

© 2025 World Lifestyler

No Result
View All Result
  • Home

© 2025 World Lifestyler